HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Matrixx Zicam “Cold Monster” Campaign Claims Fail NAD Test

This article was originally published in The Tan Sheet

Executive Summary

NAD recommends Matrixx discontinue using “Don’t let a monster of a cold catch you” in print and online ads because the claims “could reasonably be understood by consumers” to mean Zicam products prevent colds. ProPhase Labs, maker of the rival zinc-containing homeopathic Cold-EEZE line, challenges the Zicam ads.

You may also be interested in...



Zicam Creates A Monster With Reanimated Brand

Matrixx aims to make more consumers aware they can shorten the duration of a cold rather than treat the symptoms without affecting how long the cold lasts. New advertising introduces the “Cold Monster” to remind consumers to use Zicam products when they feel the first signs of a “monster of a cold.”

Matrixx Rejected On ProPhase Labs Bid, Picks Up Option On Shares

In a bid to dominate the market for zinc cold remedies, Matrixx Initiatives attempts to acquire ProPhase Labs, but is turned away by CEO Ted Karkus who asserts ProPhase’s growth prospects outweigh the benefits of a sale.

People In Brief

Herbalife brings on Dentali as botanical sciences VP; NACDS expands Nicholson’s role; Innophos announces interim CFO; George Hamilton new face of Infusion Life Sciences; Aker BioMarine names sales VP; Atteryd to chair Food Supplements Europe.

Topics

Related Companies

UsernamePublicRestriction

Register

RS124310

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel